ArticleFuture oncology (London, England)2020
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Article in Future oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03190967 (Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- [Tonsillar malignant melanoma presenting as sore throat and tonsillar mass: a case report and literature review].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026Review
- Drug treatment of breast cancer brain metastases: progress and challenges.Discover oncology · 2025Review
- Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain.Cancer cell · 2024Article
- Prevention of Brain Metastases: A New Frontier.Cancers · 2024Review
- Navigating breast cancer brain metastasis: Risk factors, prognostic indicators, and treatment perspectives.World journal of clinical oncology · 2024Article
- The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.Journal of hematology & oncology · 2024Review
- Temozolomide alleviates breast carcinoma via the inhibition of EGFR/ERK/ MMP-1 pathway with induction of apoptotic events.Acta cirurgica brasileira · 2024Article
- CMA mediates resistance in breast cancer models.Cancer cell international · 2023Article
- Leveraging translational insights toward precision medicine approaches for brain metastases.Nature cancer · 2023Review
- Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Distinct tumor architectures for metastatic colonization of the brain.bioRxiv : the preprint server for biology · 2023Article
- Copper-related genes predict prognosis and characteristics of breast cancer.Frontiers in immunology · 2023Article
- Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.Frontiers in pharmacology · 2023Review
- Review
- HER2-positive breast cancer brain metastasis: A new and exciting landscape.Cancer reports (Hoboken, N.J.) · 2022Review
- Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?Neuro-oncology · 2022Article
- The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.Neuro-oncology · 2022Article
- Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain.Nature cancer · 2022Article
- Antibody-drug conjugates in HER2-positive breast cancer.Chinese medical journal · 2021Review
- The microenvironment of brain metastases from solid tumors.Neuro-oncology advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
Abstract
Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.